Ensysce Biosciences Stock Z Score

ENSC Stock  USD 5.34  0.05  0.93%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Ensysce Biosciences Piotroski F Score and Ensysce Biosciences Valuation analysis.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
  
At present, Ensysce Biosciences' Capital Expenditures is projected to increase slightly based on the last few years of reporting. The current year's Total Debt To Capitalization is expected to grow to 2.26, whereas Capital Lease Obligations is forecasted to decline to 0.00. At present, Ensysce Biosciences' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 9.9 M, whereas Interest Income is forecasted to decline to about 93.6 K.

Ensysce Biosciences Company Z Score Analysis

Ensysce Biosciences' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Ensysce Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Ensysce Biosciences is extremely important. It helps to project a fair market value of Ensysce Stock properly, considering its historical fundamentals such as Z Score. Since Ensysce Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ensysce Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ensysce Biosciences' interrelated accounts and indicators.
0.880.961.0-0.97-0.10.771.01.0-0.76-0.8-0.30.47-1.0-0.17-0.550.090.55-0.830.75
0.880.850.88-0.85-0.130.890.880.89-0.67-0.69-0.30.4-0.89-0.19-0.520.030.45-0.730.65
0.960.850.96-0.98-0.040.730.960.97-0.58-0.83-0.10.5-0.96-0.09-0.540.170.67-0.90.87
1.00.880.96-0.97-0.130.771.01.0-0.76-0.79-0.320.46-1.0-0.2-0.570.060.53-0.830.75
-0.97-0.85-0.98-0.97-0.04-0.74-0.97-0.970.620.840.09-0.610.970.030.47-0.24-0.70.87-0.88
-0.1-0.13-0.04-0.13-0.04-0.14-0.13-0.130.18-0.280.720.320.130.940.810.960.670.170.35
0.770.890.730.77-0.74-0.140.780.78-0.66-0.63-0.230.36-0.77-0.12-0.420.070.43-0.630.58
1.00.880.961.0-0.97-0.130.781.0-0.76-0.79-0.320.46-1.0-0.2-0.570.060.53-0.830.74
1.00.890.971.0-0.97-0.130.781.0-0.75-0.79-0.310.46-1.0-0.2-0.580.060.53-0.840.75
-0.76-0.67-0.58-0.760.620.18-0.66-0.76-0.750.630.69-0.080.750.180.290.09-0.150.3-0.28
-0.8-0.69-0.83-0.790.84-0.28-0.63-0.79-0.790.630.02-0.340.79-0.340.08-0.45-0.780.54-0.85
-0.3-0.3-0.1-0.320.090.72-0.23-0.32-0.310.690.020.390.320.690.510.750.57-0.030.34
0.470.40.50.46-0.610.320.360.460.46-0.08-0.340.39-0.460.2-0.10.460.63-0.570.64
-1.0-0.89-0.96-1.00.970.13-0.77-1.0-1.00.750.790.32-0.460.20.57-0.06-0.530.83-0.75
-0.17-0.19-0.09-0.20.030.94-0.12-0.2-0.20.18-0.340.690.20.20.870.920.640.290.33
-0.55-0.52-0.54-0.570.470.81-0.42-0.57-0.580.290.080.51-0.10.570.870.680.190.71-0.18
0.090.030.170.06-0.240.960.070.060.060.09-0.450.750.46-0.060.920.680.83-0.040.55
0.550.450.670.53-0.70.670.430.530.53-0.15-0.780.570.63-0.530.640.190.83-0.540.93
-0.83-0.73-0.9-0.830.870.17-0.63-0.83-0.840.30.54-0.03-0.570.830.290.71-0.04-0.54-0.77
0.750.650.870.75-0.880.350.580.740.75-0.28-0.850.340.64-0.750.33-0.180.550.93-0.77
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

According to the company's disclosures, Ensysce Biosciences has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Ensysce Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ensysce Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ensysce Biosciences could also be used in its relative valuation, which is a method of valuing Ensysce Biosciences by comparing valuation metrics of similar companies.
100%
Ensysce Biosciences is currently under evaluation in z score category among its peers.

Ensysce Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ensysce Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ensysce Biosciences' managers, analysts, and investors.
72.0%
Environmental
74.4%
Governance
Social

Ensysce Biosciences Institutional Holders

Institutional Holdings refers to the ownership stake in Ensysce Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ensysce Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ensysce Biosciences' value.
Shares
Main Street Group Ltd2024-09-30
0.0
Renaissance Technologies Corp2024-12-31
0.0
Vanguard Group Inc2024-12-31
0.0
Geode Capital Management, Llc2024-12-31
0.0
Anson Funds Management Lp2024-12-31
0.0
Virtu Financial Llc2024-09-30
0.0
Xtx Topco Ltd2024-09-30
0.0
Hrt Financial Llc2024-12-31
0.0
Sabby Management Llc2024-09-30
1.2 M
Perceptive Advisors Llc2024-12-31
86.7 K
Adage Capital Partners Gp Llc2024-12-31
50 K

Ensysce Fundamentals

Return On Equity-2.05
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-15,000,000%-10,000,000%-5,000,000%0%
Return On Asset-0.63
Profit Margin(1.79) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,200%-1,000%-800%-600%-400%-200%
Operating Margin0.19 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%
Current Valuation3.27 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%-15%-10%-5%
Shares Outstanding1.3 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Shares Owned By Insiders1.17 %
Shares Owned By Institutions24.06 %
Number Of Shares Shorted37.81 K
Price To Book1.02 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-2,500%-2,000%-1,500%-1,000%-500%0%
Price To Sales1.59 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Revenue2.23 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Gross Profit(1.23 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%
EBITDA(10.72 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%
Net Income(10.63 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%20,000%40,000%60,000%80,000%100,000%
Cash And Equivalents3.15 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-70%-60%-50%-40%-30%-20%-10%
Cash Per Share0.10 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%0%
Total Debt854.7 K
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%
Debt To Equity6.91 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100,000%-80,000%-60,000%-40,000%-20,000%
Current Ratio0.87 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Book Value Per Share7.47 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%0%
Cash Flow From Operations(10.78 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-4,000%-2,000%0%2,000%4,000%6,000%8,000%
Short Ratio0.60 X
Earnings Per Share(31.50) X
Target Price52.25
Beta0.55
Market Capitalization7.03 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%-15%-10%-5%
Total Asset2.71 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%0%
Retained Earnings(121.56 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100,000%200,000%300,000%
Working Capital(1.04 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset2.71 M

About Ensysce Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ensysce Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ensysce Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ensysce Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:
Check out Ensysce Biosciences Piotroski F Score and Ensysce Biosciences Valuation analysis.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(31.50)
Revenue Per Share
10.216
Quarterly Revenue Growth
6.853
Return On Assets
(0.63)
Return On Equity
(2.05)
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.